Bennett Coleman & Co, Globe Telecom and Tencent are set to exit the story sharing community operator in a cash-and-stock acquisition transaction by Naver.

Lilly Asia Ventures is the largest shareholder of liver disease therapy developer Terns, which closed a $97.7m round earlier this month.

PureTech Health, Johnson & Johnson and Novartis are in line for exits after the cancer drug developer filed for its initial public offering.

The immunotherapy developer plans to go public in the United States having raised $565m from investors including Eli Lilly and WuXi AppTec.

Cambrian Biopharma is the largest investor in cancer immunotherapy developer Sensei Biotherapeutics, which has filed to raise up to $100m.

Biohaven has purchased the 58% stake cancer immunotherapy developer Kleo Pharmaceuticals it did not already own.

Klingel subsidiary K-Invest is set to exit the online content analysis tool provider in a purchase of undisclosed size by peer Unicepta.

The drama content producer, which counts iQiyi among its investors, has gone public in Hong Kong and seen its share price rise 84% on its first day of trading.

The stem cell therapy developer has filed to go public seven months after closing $700m in funding from investors including Alphabet unit GV.

Advance Publications, Cisco, Intel, Fortinet and VMWare have exited the cloud security technology producer in a purchase by Entrust.